Today’s Stock Market in 2-Minutes
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
Watch the replay of Axe Compute's Second Quarter 2026 earnings conference call, originally held live on Monday, August 17, 2026 at 8:30 a.m. Eastern Time. Christopher Miglino, Chief Executive Officer; Kyle Okamoto, President; and Jeremy Yaukey-Witter, Chief Financial Officer, review the Company's Q2 2026 financial results, recent business developments, and priorities for the second half of 2026. Key highlights discussed on the call: Revenue grew more than 90x sequentially in the Company's first full quarter of compute operations Customer prepayments grew from $0.8 million to $60.8 million, with $17.4 million in operating cash flow in the first half of 2026 The $260 million dedicated cluster of 2,304 NVIDIA B300 GPUs progressed through build, targeted for Q3 2026 go-live Total 2026 signed contracted value now exceeds $3 billion Read the full press release and financial statements on Axe Compute's investor website.
August 17, 2026PALO ALTO, Calif., Aug. 15, 2024 /PRNewswire/ — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced that it launched its Japanese-language short drama “ドS社長と死にゆく奥様の百日戦争” on August 13th at FlexTV. The intense emotional confrontations in the drama are like sharp lancet blades, precisely dissecting the dark sides of the characters’ inner selves. This compels the audience […]
August 15, 2024
FREDERICK, Md., Oct. 07, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today confirmed that it is prepared to support any increase in request for preparedness planning, equipment and decontamination services, and to provide front-line support for local or regional outbreaks anywhere in the world. […]
October 7, 2026
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO […]
October 6, 2026
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone […]
October 7, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026
October 8, 2026